Acadia Pharmaceuticals Inc (ACAD): Next-Year EPS Estimate 97.54%
As of 2026-06-04, Acadia Pharmaceuticals Inc (ACAD) has a next-year EPS growth estimate of 97.54%.
On 2026-05-24, analyst consensus for ACAD's next-year EPS growth shifted from 97.30% to 97.54% — a positive change of 0.24 percentage points. The revised estimate has been sustained across 10 subsequent trading sessions. Current-year growth is projected at -83.08%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 97.54%
- EPS growth this year
- -83.08%
- EPS next quarter (est)
- $0.06
- Last price
- $21.72
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 97.54% | -83.08% | $0.06 | $21.72 |
| 2026-06-03 | 97.54% | -83.08% | $0.06 | $21.43 |
| 2026-06-02 | 97.54% | -83.08% | $0.06 | $20.89 |
| 2026-06-01 | 97.54% | -83.08% | $0.06 | $21.52 |
| 2026-05-31 | 97.54% | -83.08% | $0.06 | $21.66 |
| 2026-05-28 | 97.54% | -83.08% | $0.06 | $21.63 |
| 2026-05-27 | 97.54% | -83.08% | $0.06 | $21.19 |
| 2026-05-26 | 97.54% | -83.08% | $0.06 | $21.26 |
| 2026-05-25 | 97.54% | -83.08% | $0.06 | $21.10 |
| 2026-05-24 | 97.54% | -83.08% | $0.06 | $21.10 |
| 2026-05-21 | 97.30% | -83.06% | $0.06 | $21.32 |
| 2026-05-20 | 97.30% | -83.06% | $0.06 | $20.95 |
| 2026-05-19 | 97.30% | -83.06% | $0.06 | $20.48 |
| 2026-05-18 | 97.30% | -83.06% | $0.06 | $20.69 |
| 2026-05-17 | 97.30% | -83.06% | $0.06 | $21.40 |
| 2026-05-14 | 97.30% | -83.06% | $0.06 | $22.09 |
| 2026-05-13 | 97.30% | -83.06% | $0.06 | $21.83 |
| 2026-05-12 | 97.30% | -83.06% | $0.06 | $21.72 |
| 2026-05-11 | 96.75% | -82.84% | $0.06 | $21.80 |
| 2026-05-10 | 96.75% | -82.84% | $0.06 | $22.40 |
| 2026-05-07 | 92.18% | -82.12% | $0.08 | $22.56 |
| 2026-05-06 | 88.70% | -80.71% | $0.05 | $21.48 |
| 2026-05-05 | 88.70% | -80.71% | $0.05 | $22.35 |
| 2026-05-04 | 88.70% | -80.71% | $0.05 | $22.19 |
| 2026-05-03 | 88.70% | -80.71% | $0.05 | $21.95 |
| 2026-04-30 | 88.70% | -80.71% | $0.05 | $22.45 |
| 2026-04-29 | 88.88% | -80.73% | $0.05 | $22.20 |
| 2026-04-28 | 88.88% | -80.73% | $0.05 | $22.67 |
| 2026-04-27 | 88.88% | -80.73% | $0.05 | $22.30 |
| 2026-04-26 | 88.88% | -80.73% | $0.05 | $21.96 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Acadia Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Acadia Pharmaceuticals Inc (ACAD) has a next-year EPS growth estimate of 97.54%, based on analyst consensus.
When was the latest EPS estimate revision for ACAD?▾
The most recent revision occurred on 2026-05-24, when analysts adjusted the next-year EPS growth estimate from 97.30% to 97.54%.
What sector and industry does Acadia Pharmaceuticals Inc belong to?▾
Acadia Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ACAD appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Acadia Pharmaceuticals Inc (ACAD) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports